These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

552 related articles for article (PubMed ID: 30319054)

  • 21. Evaluation of serum mesothelin in malignant and benign ovarian masses.
    Ibrahim M; Bahaa A; Ibrahim A; El Hakem AA; Abo-El Noor A; El Tohamy U
    Arch Gynecol Obstet; 2014 Jul; 290(1):107-13. PubMed ID: 24445964
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Loss/Down-regulation of tumor suppressor in lung cancer 1 expression is associated with tumor progression and is a biomarker of poor prognosis in ovarian carcinoma.
    Yang G; He W; Cai M; Luo F; Kung H; Guan X; Zeng Y; Xie D
    Int J Gynecol Cancer; 2011 Apr; 21(3):486-93. PubMed ID: 21436696
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mesothelin Expression in Patients with High-Grade Serous Ovarian Cancer Does Not Predict Clinical Outcome But Correlates with CD11c
    Magalhaes I; Fernebro J; Abd Own S; Glaessgen D; Corvigno S; Remberger M; Mattsson J; Dahlstrand H
    Adv Ther; 2020 Dec; 37(12):5023-5031. PubMed ID: 33052561
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Study of apoptosis and Fas expression of peritoneal fluid and peripheral blood T lymphocytes in patients with epithelial ovarian cancer and their relationship with CA125].
    Ma YX; Ye F; Chen HZ; Lü WG; Xie X
    Zhonghua Yi Xue Za Zhi; 2007 Mar; 87(11):734-9. PubMed ID: 17565840
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Periostin in tumor microenvironment is associated with poor prognosis and platinum resistance in epithelial ovarian carcinoma.
    Sung PL; Jan YH; Lin SC; Huang CC; Lin H; Wen KC; Chao KC; Lai CR; Wang PH; Chuang CM; Wu HH; Twu NF; Yen MS; Hsiao M; Huang CY
    Oncotarget; 2016 Jan; 7(4):4036-47. PubMed ID: 26716408
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lack of MRE11-RAD50-NBS1 (MRN) complex detection occurs frequently in low-grade epithelial ovarian cancer.
    Brandt S; Samartzis EP; Zimmermann AK; Fink D; Moch H; Noske A; Dedes KJ
    BMC Cancer; 2017 Jan; 17(1):44. PubMed ID: 28073364
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Expression of p53 protein phosphorylated at serine 20 and serine 392 in malignant and benign ovarian neoplasms: correlation with clinicopathological parameters of tumors.
    Bar JK; Słomska I; Rabczyńki J; Noga L; Gryboś M
    Int J Gynecol Cancer; 2009 Nov; 19(8):1322-8. PubMed ID: 20009884
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Expression and correlation of Lewis y antigen and integrins α5 and β1 in ovarian serous and mucinous carcinoma.
    Li Q; Liu S; Lin B; Yan L; Wang Y; Wang C; Zhang S
    Int J Gynecol Cancer; 2010 Dec; 20(9):1482-9. PubMed ID: 21119363
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Vascular endothelial growth factor activating matrix metalloproteinase in ascitic fluid during peritoneal dissemination of ovarian cancer.
    Yabushita H; Shimazu M; Noguchi M; Kishida T; Narumiya H; Sawaguchi K; Noguchi M
    Oncol Rep; 2003; 10(1):89-95. PubMed ID: 12469150
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Correlation Between Tumor Mesothelin Expression and Serum Mesothelin in Patients with Epithelial Ovarian Carcinoma: A Potential Noninvasive Biomarker for Mesothelin-targeted Therapy.
    Hanaoka T; Hasegawa K; Kato T; Sato S; Kurosaki A; Miyara A; Nagao S; Seki H; Yasuda M; Fujiwara K
    Mol Diagn Ther; 2017 Apr; 21(2):187-198. PubMed ID: 28160193
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Difference in mesothelin-binding ability of serum CA125 between patients with endometriosis and epithelial ovarian cancer.
    Sasaki A; Akita K; Ito F; Mori T; Kitawaki J; Nakada H
    Int J Cancer; 2015 Apr; 136(8):1985-90. PubMed ID: 25197000
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Different levels of sialyl-Tn antigen expressed on MUC16 in patients with endometriosis and ovarian cancer.
    Akita K; Yoshida S; Ikehara Y; Shirakawa S; Toda M; Inoue M; Kitawaki J; Nakanishi H; Narimatsu H; Nakada H
    Int J Gynecol Cancer; 2012 May; 22(4):531-8. PubMed ID: 22367369
    [TBL] [Abstract][Full Text] [Related]  

  • 33. HSP60 predicts survival in advanced serous ovarian cancer.
    Hjerpe E; Egyhazi S; Carlson J; Stolt MF; Schedvins K; Johansson H; Shoshan M; Avall-Lundqvist E
    Int J Gynecol Cancer; 2013 Mar; 23(3):448-55. PubMed ID: 23429486
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
    Shao HL; Shen DH; Xue WC; Li Y; Yu YZ
    Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Utility of mesothelin, L1CAM and Afamin as biomarkers in primary ovarian cancer.
    Aktas B; Kasimir-Bauer S; Wimberger P; Kimmig R; Heubner M
    Anticancer Res; 2013 Jan; 33(1):329-36. PubMed ID: 23267165
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High levels of pretreatment CA125 are associated to improved survival in high grade serous ovarian carcinoma.
    Morales-Vásquez F; Pedernera E; Reynaga-Obregón J; López-Basave HN; Gómora MJ; Carlón E; Cárdenas S; Silva-Ayala R; Almaraz M; Méndez C
    J Ovarian Res; 2016 Jul; 9(1):41. PubMed ID: 27388275
    [TBL] [Abstract][Full Text] [Related]  

  • 37. IL17a and IL21 combined with surgical status predict the outcome of ovarian cancer patients.
    Chen YL; Chou CY; Chang MC; Lin HW; Huang CT; Hsieh SF; Chen CA; Cheng WF
    Endocr Relat Cancer; 2015 Oct; 22(5):703-11. PubMed ID: 26150382
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Peritoneal dissemination of ovarian cancer: role of MUC16-mesothelin interaction and implications for treatment.
    Coelho R; Marcos-Silva L; Ricardo S; Ponte F; Costa A; Lopes JM; David L
    Expert Rev Anticancer Ther; 2018 Feb; 18(2):177-186. PubMed ID: 29241375
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inflammation-regulating factors in ascites as predictive biomarkers of drug resistance and progression-free survival in serous epithelial ovarian cancers.
    Lane D; Matte I; Garde-Granger P; Laplante C; Carignan A; Rancourt C; Piché A
    BMC Cancer; 2015 Jul; 15():492. PubMed ID: 26122176
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Overexpression of Annexin A1 Is an Independent Predictor of Longer Overall Survival in Epithelial Ovarian Cancer.
    Manai M; Doghri R; Finetti P; Mrad K; Bouabsa R; Manai M; Birnbaum D; Bertucci F; Charfi L; Driss M
    In Vivo; 2020; 34(1):177-184. PubMed ID: 31882477
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.